(Updates with reporting date in the first paragraph, and the latest stock move in the headline and first paragraph)
argenx (ARGX) shares rose more than 16% in Monday trading after the company said a phase 3 study evaluating its experimental drug, Vyvgart Hytrulo, in adults with autoimmune myositis met its main goal.
The company said the patients treated with the drug showed a statistically significant improvement in mean total improvement score at week 52 compared with placebo.
Treatment benefits emerged as early as week 4 and were sustained through the 52-week treatment period, including during steroid tapering, the company said.
argenx said the primary endpoint was also met in patients with immune-mediated necrotizing myopathy, while dermatomyositis patients showed a similar improvement, although it did not reach statistical significance.
Price: $989.87, Change: $+138.58, Percent Change: +16.28%